Quarterly ResultMay 6, 2026, 04:07 PM
Sight Sciences Q1 Revenue $19.7M, +13%; Raises FY26 Guidance
AI Summary
Sight Sciences, Inc. reported strong financial results for the first quarter ended March 31, 2026, with total revenue increasing 13% year-over-year to $19.7 million, driven by significant growth in its Interventional Dry Eye segment. The company also raised its full-year 2026 revenue guidance to a range of $83.0 million to $89.0 million. Additionally, a U.S. District Court issued a final judgment in the company's patent infringement case against Alcon, awarding Sight Sciences $55.4 million in past monetary damages and an ongoing royalty of 10% on Hydrus Microstent revenue.
Key Highlights
- U.S. District Court awarded $55.4M past damages and 10% ongoing royalty in Alcon patent case.
- Q1 2026 total revenue $19.7M, up 13% year-over-year.
- Interventional Glaucoma revenue $18.3M, up 7% year-over-year.
- Interventional Dry Eye revenue $1.4M, up 244% year-over-year.
- Gross margin 86% in Q1 2026, flat year-over-year.
- Net loss $13.0M ($0.24/share) in Q1 2026, improved from $14.2M ($0.28/share) YoY.
- Cash usage reduced 40% to $7.0M in Q1 2026.
- Raised full-year 2026 revenue guidance to $83.0M-$89.0M (7%-15% growth).